Seminars in Oncology
Volume 33 , Pages 3-11 , April 2006

Systemic Therapy for Ovarian Cancer: Current Status and New Treatments

  • Robert F. Ozols

      Affiliations

    • Dr Ozols has served as a consultant to Bristol-Myers Squibb, Eli Lilly and Company, Genentech, and Unither Pharmaceuticals.
    • Corresponding Author InformationAddress reprint requests to Robert F. Ozols, MD, PhD, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA

References 

  1. Jemal A , Siegal R , Ward E , et al.   Cancer statistics, 2006 . CA Cancer J Clin . 2006;56:106–130
  2. Ozols RF . Advanced ovarian cancer (A clinical update on first-line treatment, recurrent disease and new agents) . J Natl Compr Cancer Netw . 2004;2:60–73
  3. Ozols RF , Bundy BN , Greer BE , et al.   Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer (A Gynecologic Oncology Group Study) . J Clin Oncol . 2003;21:3194–3200
  4. Ozols RF . Current controversies in ovarian cancer (Maintenance chemotherapy and neoadjuvant chemotherapy as standard care) . Proc Am Soc Clin Oncol Educational Book . 2004;268:268–275
  5. Ozols RF . Maintenance therapy in advanced ovarian cancer (Progression-free survival and clinical benefit) . J Clin Oncol . 2003;21:2451–2453
  6. Piccart MJ , Floquet A , Scarfone G , et al.   Intraperitoneal cisplatin versus no further treatment (8-Year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based IV chemotherapy) . Int J Gynecol Cancer . 2003;13:196–203
  7. Markman M , Liu PY , Wilczynski S , et al.   Randomized phase III trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy (A Southwest Oncology Group and Gynecologic Oncology Group trial) . J Clin Oncol . 2003;21:2460–2465
  8. Herzog T , Barret RJ , Edwards R , et al.   Phase II study of paclitaxel poliglumex (PPX)/carboplatin (C) for 1st line induction and maintenance therapy of stage III/IV ovarian or primary peritoneal carcinoma . Proc Am Soc Clin Oncol . 2005;24:S458; (abstr)
  9. GOG Protocol 0212: A randomized phase III trial of maintenance chemotherapy comparing 12, monthly cycles of single agent Paclitaxel or Xyotax™ (CT-2103) (IND #70177) versus no treatment until documented relapse in women with advanced ovarian or primary peritoneal cancer who achieve a complete clinical response to primary platinum/taxane chemotherapy. Available at: http://www.clinicaltrials.gov/ct/show/NCT00108745?order=2 (accessed March 30, 2006)
  10. Hall G , Brown JM , Coleman RE , et al.   Maintenance treatment with interferon for advanced ovarian cancer (results of the Northern and Yorkshire gynaecology group randomised phase III study) . Br J Cancer . 2004;91:621–626
  11. Hirte HW , Vergote IB , Jeffrey JR , et al.   An international multicentre phase III study of BAY 12-9566 (BAY) versus placebo in patients (pts) with advanced ovarian cancer (OVCA) responsive to primary surgery/paclitaxel + platinum containing chemotherapy (CT) . Proc Am Soc Clin Oncol . 2001;20:211a; (abstr)
  12. Berek JS , Taylor PT , Gordon A , et al.   Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer . J Clin Oncol . 2004;22:3507–3516
  13. Alberts DS , Liu PY , Hannigan EV , et al.   Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer . N Engl J Med . 1996;335:1950–1955
  14. Markman M , Bundy BN , Alberts DS , et al.   Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma (An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group) . J Clin Oncol . 2001;19:1001–1007
  15. Armstrong DK , Bundy BN , Baergen R , et al.   Randomized phase III study of intravenous paclitaxel and cisplatin versus IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (A Gynecologic Oncology Group trial (GOG 172)) . Proc Am Soc Clin Oncol . 2002;21:803; (abstr)
  16. Ozols RF . Counterpoint: Intraperitoneal chemotherapy: an investigational treatment in ovarian cancer . J Natl Compr Cancer Netw . 2004;2:555–560
  17. Vasey PA , Jayson GC , Gordon A , et al.   Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma . J Natl Cancer Inst . 2004;96:1682–1691
  18. Randomized comparison of gemcitabine plus carboplatin versus paclitaxel plus carboplatin in previously untreated ovarian cancer. Eli Lilly & Co. trial (in progress). Available at: http://www.clinicaltrials.gov/ct/show/NCT00191646?order=3 (accessed March 30, 2006)
  19. Pignata S , Scambia G , Savarese A , et al.   Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC) (Preliminary safety results of the MITO-2 randomized multicenter trial) . Proc Am Soc Clin Oncol . 2005;24:S458; (abstr)
  20. du Bois A , Combe M , Rochon J , et al.   Epirubicin/paclitaxel/carboplatin (TEC) vs. paclitaxel/carboplatin (TC) in first-line treatment of ovarian cancer (OC) FIGO stages IIB-IV. An AGO-GINECO Intergroup phase III trial . Proc Am Soc Clin Oncol . 2004;23:S450; (abstr)
  21. Look KY , Bookman MA , Schol J , et al.   Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer (A Gynecologic Oncology Group study) . Gynecol Oncol . 2004;92:93–100
  22. Hoskins P , Eisenhauer E , Vergote I , et al.   Phase II feasibility study of sequential couplets of cisplatin/topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer (A National Cancer Institute of Canada Clinical Trials Group Study) . J Clin Oncol . 2000;18:4038–4044
  23. Rose P , Greer B , Markman M , et al.   A phase I study of paclitaxel, carboplatin, and liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma (A Gynecologic Oncology Group study) . Proc Am Soc Clin Oncol . 2000;19:387a; (abstr)
  24. Bookman MA . Developmental chemotherapy and management of recurrent ovarian cancer . J Clin Oncol . 2003;21:149–167
  25. Gore M . Treatment of relapsed epithelial ovarian cancer . In:  Perry MC editors. 2001 American Society of Clinical Oncology Annual Meeting Educational Book . Alexandria, VA: American Society of Clinical Oncology; 2001;p. 468–476
  26. Parmar MK , Ledermann JA , Colombo N , et al.   Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer (The ICON4/AGO-OVAR-2.2 trial) . Lancet . 2003;361:2099–2106
  27. Pfisterer J , Plante M , Vergote I , et al.   Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum-sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG . J Clin Oncol . 2004;22:5005; (abstr)
  28. Vermorken JB , Parmar MKB , Brady MF , et al.   Clinical trials in ovarian carcinoma (Study methodology) . Ann Oncol . 2005;16:20–29
  29. Kaye SB . Chemotherapy for ovarian cancer (future potential for new and existing drugs) . In:  Perry MC editors. 2005 American Society of Clinical Oncology Annual Meeting Educational Book . Alexandria, VA: American Society of Clinical Oncology; 2005;
  30. Kavanagh JJ , Gershenson DM , Choi H , et al.   Multi-institutional phase II study of TLK286 (TELCYTA, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer . Int J Gynecol Cancer . 2005;15:411–415
  31. Phase III randomized study of TELCYTA (TLK286) versus liposomal doxorubicin or topotecan as third-line therapy in platinum refractory or platinum-resistant ovarian cancer. Clinical trial conducted by Telik (in progress). Available at: http://www.clinicaltrials.gov/ct/show/NCT00102973?order=1 (accessed March 30, 2006)
  32. Colombo N , Capri G , Bauer J , et al.   Phase II and pharmacokinetics study of 3-hr infusion of ET-743 in ovarian cancer patients failing platinum-taxanes . Proc Am Soc Clin Oncol . 2001;21:221a; (abstr)
  33. Zhao R , Babani S , Gao F , et al.   The mechanism of transport of the multitargeted antifolate, (MTA) and its cross-resistant pattern in cells with markedly impaired transport of methotrexate . Clin Cancer Res . 2000;6:3687–3695
  34. Theti DS , Jackman AL . The role of α-folate receptor-mediated transport in the antitumor activity of antifolate drugs . Clin Cancer Res . 2004;10:1080–1089
  35. Zhao R , Zhang S , Hanscom M , et al.   Loss of reduced folate carrier function and folate depletion result in enhanced pemetrexed inhibition of purine synthesis . Clin Cancer Res . 2005;11:1294–1301
  36. Wu M , Gunning W , Ratnam M . Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix . Cancer Epidemiol Biomarkers Prev . 1999;8:775–782
  37. Vogelzang NJ , Rusthoven JJ , Symanowski  , et al.   Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma . J Clin Oncol . 2003;21:2636–2644
  38. Hanna N , Shepherd FA , Fossella FV , et al.   Randomized phase III trial of pemetrexed versus docetaxel in patients with non–small-cell lung cancer previously treated with chemotherapy . J Clin Oncol . 2004;22:1589–1597
  39. Eli Lilly and Company: Phase I studies of pemetrexed. Indianapolis, IN, Eli Lilly and Company
  40. Eli Lilly and Company: Phase I study of pemetrexed and gemcitabine. Indianapolis, IN, Eli Lilly and Company
  41. Eli Lilly and Company: Randomized phase II trial of pemetrexed and carboplatin. Indianapolis, IN, Eli Lilly and Company
  42. Worzalla JF , Shih C , Schultz RM . Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY231514 . Anticancer Res . 1998;18:3235–3239
  43. Schilder RJ . Novel therapies (Update on biologic targeted strategies for ovarian cancer) . In:  Perry MC editors. 2005 American Society of Clinical Oncology Annual Meeting Educational Book . Alexandria, VA: American Society of Clinical Oncology; 2005;p. 421–428
  44. Finkler N , Gordon A , Crozier M , et al.   Phase II evaluation of OSI-774, a potential oral antagonist of the EGFR-TK in patients with advanced ovarian cancer . Proc Am Soc Clin Oncol . 2001;20:208a; (abstr)
  45. Schilder RJ , Kohn E , Sill MW , et al.   Phase II trial of gefitinib in patients with recurrent ovarian or primary peritoneal cancer (Gynecologic Oncology Group 170C) . Proc Am Soc Clin Oncol . 2003;22:451; (abstr)
  46. Schilder RJ , Sill MW , Chen X , et al.   Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression (A Gynecologic Oncology Group study) . Clin Cancer Res . 2005;11:5539–5548
  47. Aghajanian C , Sabbatini P , Derosa F , et al.   A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced stage ovarian, primary peritoneal, and fallopian tube cancer . Proc Am Soc Clin Oncol . 2005;24:466; (abstr)
  48. Schilder RJ: Phase II trial of cetuximab in recurrent ovarian cancer. Philadelphia, PA, Fox Chase Cancer Center
  49. Spector N , Raefsky E , Hurwitz H , et al.   Safety, clinical efficacy, and biologic assessments from EGF 10004 (A randomized phase IB study of GW572016 for patient with metastatic carcinomas overexpressing EGFR or erbB2) . Proc Am Soc Clin Oncol . 2003;22:193; (abstr)
  50. Gordon MS , Matei D , Aghajanian C , et al.   Clinical activity of pertuzimab (rhuMab 2C4) in advanced, refractory or recurrent ovarian cancer (OC), and the role of HER2 activation status . Proc Am Soc Clin Oncol . 2005;24:467s; (abstr)
  51. Hu L , Hofmann J , Zaloudak C , et al.   Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer . Am J Pathol . 2002;161:1917–1924
  52. Burger RA , Sill M , Monk BJ , et al.   Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC) (A Gynecologic Oncology Group (GOG) study) . Proc Am Soc Clin Oncol . 2005;24:457; (abstr)
  53. Garcia AA , Oza AM , Hirte H , et al.   Interim report of a phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma (A California Cancer Consortium trial) . Proc Am Soc Clin Oncol . 2005;24:455s; (abstr)
  54. Sandler AB , Gray R , Brahmer J , et al.   Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non–small cell lung cancer (NSCLC) (An Eastern Cooperative Oncology Group (ECOG) trial - E4599) . Proc Am Soc Clin Oncol . 2005;24:2s; (abstr)
  55. Hampton T . Monoclonal antibody therapies shine in breast cancer clinical trials . JAMA . 2005;293:2985–2989
  56. Hurwitz H , Fehrenbacher L , Novotny W , et al.   Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer . N Engl J Med . 2004;350:2335–2342
  57. Goekjian PG , Jirousek MR . Protein kinase C inhibitors as novel anticancer drugs . Expert Opin Invest Drugs . 2001;10:2117–2140
  58. Graff JR , McNulty AM , Hanna KR , et al.   The protein kinase Cβ-selective inhibitor, enzastaurin (LY317615.HCI), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts . Cancer Res . 2005;65:7462–7469
  59. Teicher BA , Menon K , Alvarez E , et al.   Antiangiogenic and antitumor effects of a protein kinase Cβ inhibitor in human breast cancer and ovarian cancer xenografts . Invest New Drugs . 2002;20:241–251
  60. Keyes KA , Mann L , Sherman M , et al.   LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice . Cancer Chemother Pharmacol . 2004;53:133–140
  61. Herbst RS , Thornton DE , Kies MS , et al.   Phase I study of LY317615, a protein kinase Cβ inhibitor . Proc Am Soc Clin Oncol . 2002;21:82a; (abstr)
  62. Fine HA , Kim L , Royce C , et al.   Results from phase II trial of enzastaurin (LY317615) in patients with recurrent high grade gliomas . Proc Am Soc Clin Oncol . 2005;23:115s; (abstr)
  63. Gasparini G , Longo R , Fanelli M , et al.   Combination of antiangiogenic therapy with other anticancer therapies (results, challenges, and open questions) . J Clin Oncol . 2005;23:1295–1311

PII: S0093-7754(06)00118-7

doi: 10.1053/j.seminoncol.2006.03.011

Seminars in Oncology
Volume 33 , Pages 3-11 , April 2006

Article Tools

* Image Usage & Resolution